Highlight
This multi-institutional retrospective study identifies that cutaneous adverse events (cAEs) specifically induced by enfortumab vedotin (EV) in locally advanced or metastatic urothelial carcinoma patients are common and independently associated with significantly improved progression-free survival (PFS) and overall survival (OS). Notably, early-onset and even high-grade EV-related skin toxicities correlate with favorable clinical outcomes. Distinguishing EV-induced cAEs from other causes is crucial for optimal management and prognostication.
